Rhinomed (ASX:RNO) - Aandelenkoers, Nieuws & Analyse

RNO Overzicht aandelen

Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide.

RNO fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Beloningen

Risicoanalyse

De winst is de afgelopen 5 jaar met 8.2% per jaar gedaald

Heeft geen betekenisvolle marktkapitalisatie ( A$12M )

Negatief eigen vermogen

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Rhinomed Limited Concurrenten

Invion

ASX:IVX

AU$13.5m

Cann Group

ASX:CAN

AU$23.9m

Firebrick Pharma

ASX:FRE

AU$12.0m

Emyria

ASX:EMD

AU$12.5m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Rhinomed
Historische aandelenkoersen
Huidige aandelenkoers	AU$0.04
52 Week Hoogtepunt	AU$0.10
52 Week Laag	AU$0.019
Bèta	0.88
11 maand verandering	60.00%
3 maanden verandering	33.33%
1 Jaar Verandering	-55.56%
33 jaar verandering	-66.67%
5 jaar verandering	-74.19%
Verandering sinds IPO	-99.41%

Recent nieuws en updates

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 10

Recent updates

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 10

Rendement voor aandeelhouders

	RNO	AU Pharmaceuticals	AU Markt
7D	-7.0%	4.4%	0.7%
1Y	-55.6%	63.3%	16.7%

Rendement versus industrie: RNO presteerde slechter dan de Australian Pharmaceuticals -sector, die het afgelopen jaar een rendement van 63.3 % opleverde.

Rendement versus markt: RNO presteerde slechter dan Australian Market, dat het afgelopen jaar een rendement van 16.7 % opleverde.

Prijsvolatiliteit

Is RNO's price volatile compared to industry and market?
RNO volatility
RNO Average Weekly Movement	26.2%
Pharmaceuticals Industry Average Movement	11.5%
Market Average Movement	8.5%
10% most volatile stocks in AU Market	17.2%
10% least volatile stocks in AU Market	3.5%

Stabiele aandelenkoers: De aandelenkoers van RNO is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van RNO is het afgelopen jaar gestegen van 19% naar 26%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2004	n/a	Michael Johnson	www.rhinomed.global

Rhinomed Limited Samenvatting

Hoe verhouden de winst en inkomsten van Rhinomed zich tot de beurswaarde?
RNO fundamentele statistieken
Marktkapitalisatie	AU$11.51m
Inkomsten(TTM)	-AU$10.91m
Inkomsten(TTM)	AU$8.05m

1.4x

P/S-verhouding

-1.1x

Koers/Winstverhouding

Is RNO overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
RNO resultatenrekening (TTM)
Inkomsten	AU$8.05m
Kosten van inkomsten	AU$2.78m
Brutowinst	AU$5.28m
Overige uitgaven	AU$16.18m
Inkomsten	-AU$10.91m

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.038
Brutomarge	65.53%
Nettowinstmarge	-135.49%
Schuld/Eigen Vermogen Verhouding	-90.4%

Hoe presteerde RNO op de lange termijn?

Bekijk historische prestaties en vergelijking

RNO Overzicht aandelen

Beloningen

Risicoanalyse

Rhinomed Limited Concurrenten

ASX:IVX

AU$13.5m

ASX:CAN

AU$23.9m

ASX:FRE

AU$12.0m

ASX:EMD

AU$12.5m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Rhinomed Limited Announces Retirement of Brent Scrimshaw, Non-Executive Director, Effective from November 17Th, 2023

Recent updates

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Rhinomed Limited Announces Retirement of Brent Scrimshaw, Non-Executive Director, Effective from November 17Th, 2023

Full year 2023 earnings released: AU$0.038 loss per share (vs AU$0.02 loss in FY 2022)

Rhinomed Limited, Annual General Meeting, Nov 17, 2023

Full year 2023 earnings released: AU$0.039 loss per share (vs AU$0.02 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Market cap size

Insider recently bought AU$242k worth of stock

Insider recently bought AU$372k worth of stock

Is Rhinomed (ASX:RNO) Using Too Much Debt?

First half 2023 earnings released: AU$0.016 loss per share (vs AU$0.013 loss in 1H 2022)

Less than half of directors are independent

Rhinomed Limited, Annual General Meeting, Nov 18, 2022

Less than half of directors are independent

Rhinomed Limited Announces Rhinoswab Junior Study Confirms New Nasal Swab Is Most Accurate, Comfortable and Easy for Kids

Rhinomed Limited Appoints Lyn Swinburne AO as Non-Executive Director

Full year 2022 earnings released: AU$0.02 loss per share (vs AU$0.034 loss in FY 2021)

Rhinomed (ASX:RNO) Is In A Strong Position To Grow Its Business

Rhinomed Limited Announces the Interim Results in the World First "Rhinoswab for Diagnosis of Respiratory Virus in Children" Trial

CEO, MD & Executive Director exercised options to buy AU$855k worth of stock.

CEO, MD & Executive Director exercised options to buy AU$855k worth of stock.

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Here's Why We're Not Too Worried About Rhinomed's (ASX:RNO) Cash Burn Situation

Non-Executive Director recently bought AU$77k worth of stock

Non-Executive Director recently bought AU$76k worth of stock

Here's Why We're Watching Rhinomed's (ASX:RNO) Cash Burn Situation

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.034 loss in 1H 2020)

Key Things To Understand About Rhinomed's (ASX:RNO) CEO Pay Cheque

Independent Non-Executive Chairman recently bought AU$180k worth of stock

Insider recently bought AU$435k worth of stock

How Many Rhinomed Limited (ASX:RNO) Shares Did Insiders Buy, In The Last Year?

Rhinomed Limited Detects SARS-CoV-2 in Doherty Inst. RT-PCR Study

Rhinomed Limited Announces Registration of Nasal Swab with Australian Therapeutic Goods Administration

Rhinomed Limited Announces Registration of Its Novel Nasal Swab with the US FDA

Insider recently bought AU$513k worth of stock

Insider recently bought AU$443k worth of stock

Insider recently bought AU$668k worth of stock

Insider recently bought AU$600k worth of stock

Rhinomed Limited Auditor Raises 'Going Concern' Doubt

Full year earnings released - AU$0.044 loss per share

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Rhinomed Limited Samenvatting

1.4x

-1.1x

Inkomsten en omzet